CSL Ltd (CSL):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:CSL Ltd (CSL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10086
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:95
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥52,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥78,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
CSL Ltd (CSL) discovers, develops, manufactures, markets and distributes biopharmaceuticals and related products. Its portfolio encompasses plasma-derived products for the treatment of bleeding disorders such as hemophilia and von Willebrand disease, hereditary angioedema, primary and secondary immune deficiencies, inherited respiratory disease and neurological disorders; influenza vaccine; and protein-based medicines for treating serious human illnesses. The company also provides products for the prevention of hemolytic disease in newborns and infection in solid organ transplant recipients and to treat specific infections and help victims of trauma, shock and burns. CSL also markets an array of vaccines, anti-venoms, and pharmaceutical products of various other manufacturers. The company sells its products in Australia, Germany, Switzerland, the UK, the US and rest of the world. CSL is headquartered in Parkville, Victoria, Australia.

CSL Ltd (CSL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
CSL Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
CSL Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
CSL Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
CSL Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
CSL Ltd, Medical Devices Deals, 2012 to YTD 2018 13
CSL Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
CSL Ltd, Pharmaceuticals & Healthcare, Deal Details 19
Asset Purchase 19
CSL Acquires Influenza Vaccines Business of Novartis for USD275 Million 19
Venture Financing 23
Calimmune Raises USD15 Million in Series B Financing 23
Partnerships 24
CSL Enters into Agreement with Vitaeris 24
PaxVax Enters into Distribution Agreement with Seqirus 25
Seqirus Enters into Distribution Agreement with Valneva 26
A1M Pharma Enters into Research Agreement with CSL Behring 27
PaxVax Enters into Distribution Agreement with BioCSL 28
Alk Abello Enters into Co-Marketing Agreement with BioCSL 29
ALK-Abello Enters into Agreement with Seqirus 30
Licensing Agreements 31
Seqirus Enters into Licensing Agreement with Glenmark Specialty 31
CSL Enters into Licensing Agreement with Cevec Pharma 32
CSL Enters into Licensing Agreement with Momenta Pharma 33
Seqirus Enters into Licensing Agreement with Zambon 35
Calimmune Enters into Licensing Agreement with Cincinnati Children’s Hospital Medical Center 36
Calimmune Enters into Licensing Agreement with Asklepios BioPharma 37
Calimmune Enters into Licensing Agreement with St. Jude Children’s Research Hospital 38
BioCryst Pharma Enters into Licensing Agreement with Seqirus 39
Aslan Pharma Enters Into Licensing Agreement With CSL For CSL-334 41
CSL Enters Into Licensing Agreement With Janssen For CSL-362 42
CSL Enters into Licensing Agreement with Xencor 43
Benitec Enters Into Licensing Agreement With Calimmune For ddRNAi Technology 44
Debt Offering 45
CSL Raises USD200 Million in Private Placement of 3.32% Debt Securities Due 2029 45
CSL Raises USD150 Million in Private Placement of 3.47% Debt Securities Due 2032 46
CSL Raises USD100 Million in Private Placement of 3.77% Debt Securities Due 2037 47
CSL Raises USD250 Million in Private Placement of 3.17% Debt Securities Due 2027 48
CSL Raises USD258 Million in Private Placement of 0.955% Debt Securities Due 2025 49
CSL Raises USD155 Million in Private Placement of 0.755% Debt Securities Due 2023 50
CSL Raises USD100 Million in Private Placement of 3.63% Debt Securities Due 2025 51
CSL Raises USD200.5 Million in Private Placement of 1.93% Debt Securities Due 2024 52
CSL Raises USD134 Million in Private Placement of 2.1% Debt Securities Due 2026 53
CSL Raises USD134 Million in Private Placement of 1.65% Debt Securities Due 2022 54
CSL Completes Private Placement Of Debt Securities Due 2023 For US$150 Million 55
CSL Completes Private Placement Of Debt Securities Due 2018 For US$100 Million 56
CSL Completes Private Placement Of Debt Securities Due 2020 For US$150 Million 57
CSL Completes Private Placement Of Debt Securities Due 2025 For US$100 Million 58
Asset Transactions 59
Paragon Care to Acquire Immunohaematology Business Unit from Seqirus for USD6.4 Million 59
Acquisition 60
CSL to Acquire Remaining 20% Stake in Wuhan Zhong Yuan Rui De Biological Products from Humanwell Healthcare Group for USD102 Million 60
CSL Behring Acquires Calimmune 61
CSL Acquires 80% Equity Stake in Wuhan Zhong Yuan Rui De Biological Products from Humanwell Healthcare Group for USD352 Million 62
CSL Ltd – Key Competitors 63
CSL Ltd – Key Employees 64
CSL Ltd – Locations And Subsidiaries 65
Head Office 65
Other Locations & Subsidiaries 65
Recent Developments 68
Strategy And Business Planning 68
Dec 07, 2017: Expansion of CSL Biotech Facility Drives Advanced Manufacturing Growth and Creates Victorian Jobs 68
Financial Announcements 69
Aug 15, 2018: CSL Delivers a Full Year Net Profit of $1.7 billion 69
Aug 16, 2017: CSL announces Full Year Result 2017 71
Feb 15, 2017: CSL Announces Half Year Result 2017 73
Jan 19, 2017: CSL reports FY2017 profit upgrade 75
Corporate Communications 76
Dec 13, 2017: CSL Appoints New Directors 76
Government and Public Interest 78
Oct 17, 2017: Australian Scientists awarded $2.5m to support ground-breaking medical research into cancer diagnostics and cardiovascular disease 78
Product News 79
09/14/2017: CSL Behring Announces FDA Approval of Privigen [Immune Globulin Intravenous (Human), 10% Liquid] for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Adults 79
08/30/2017: Momenta Pharmaceuticals to Webcast Presentation at the 2017 Wells Fargo Healthcare Conference 80
08/09/2017: Berinert Approved by Health Canada for the Treatment of Hereditary Angioedema (HAE) in Pediatric Patients 81
07/11/2017: CSL Behring Awards Researchers to Advance Immunoglobulin Therapy in Treating Neurological Disorders 82
06/15/2018: CSL Behring Presents New Data on Subcutaneous Immunoglobulin Treatment from the Largest CIDP Study, the PATH Trial, at the 4th Congress of the European Academy of Neurology 83
04/20/2018: CSL Behring, Leader in Rare Diseases, Showcases Innovations in Neuromuscular Medicine (NMM) at the 2018 American Academy of Neurology Annual Meeting 84
03/16/2018: FDA Approves Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy 85
01/26/2018: CHMP Recommends Extension of Indications for Hizentra 86
Product Approvals 87
Jul 19, 2017: FDA Accepts CSL Behrings Supplemental Biologics License Application for Hizentra Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Indication 87
Feb 14, 2017: FDA Accepts CSL Behring’s Biologics License Application Supplement for Using Privigen to Treat Chronic Inflammatory Demyelinating Polyneuropathy, a Rare Neurological Condition 88
Clinical Trials 89
Oct 03, 2018: Seqirus presents favorable outcomes data for adjuvanted trivalent influenza vaccine (FLUAD) at 6th Annual IDWeek 89
Nov 09, 2017: Lancet Neurology Publishes Results from CSL Behring Phase III Study of Hizentra (Immune Globulin Subcutaneous [Human] 20% liquid) as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy 91
Apr 04, 2017: New England Journal of Medicine Publishes Pivotal Phase III Data for CSL Behring’s Subcutaneous C1-Esterase Inhibitor in HAE Patients 92
Mar 22, 2017: NEJM Publishes Pivotal Data on Preventing HAE Attacks 93
Mar 01, 2017: CSL Behring Announces Largest Ever CIDP Clinical Study Completed 94
Appendix 95
Methodology 95
About GlobalData 95
Contact Us 95
Disclaimer 95

List of Tables
CSL Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
CSL Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
CSL Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
CSL Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
CSL Ltd, Deals By Therapy Area, 2012 to YTD 2018 11
CSL Ltd, Medical Devices Deals, 2012 to YTD 2018 13
CSL Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
CSL Acquires Influenza Vaccines Business of Novartis for USD275 Million 19
Calimmune Raises USD15 Million in Series B Financing 23
CSL Enters into Agreement with Vitaeris 24
PaxVax Enters into Distribution Agreement with Seqirus 25
Seqirus Enters into Distribution Agreement with Valneva 26
A1M Pharma Enters into Research Agreement with CSL Behring 27
PaxVax Enters into Distribution Agreement with BioCSL 28
Alk Abello Enters into Co-Marketing Agreement with BioCSL 29
ALK-Abello Enters into Agreement with Seqirus 30
Seqirus Enters into Licensing Agreement with Glenmark Specialty 31
CSL Enters into Licensing Agreement with Cevec Pharma 32
CSL Enters into Licensing Agreement with Momenta Pharma 33
Seqirus Enters into Licensing Agreement with Zambon 35
Calimmune Enters into Licensing Agreement with Cincinnati Children’s Hospital Medical Center 36
Calimmune Enters into Licensing Agreement with Asklepios BioPharma 37
Calimmune Enters into Licensing Agreement with St. Jude Children’s Research Hospital 38
BioCryst Pharma Enters into Licensing Agreement with Seqirus 39
Aslan Pharma Enters Into Licensing Agreement With CSL For CSL-334 41
CSL Enters Into Licensing Agreement With Janssen For CSL-362 42
CSL Enters into Licensing Agreement with Xencor 43
Benitec Enters Into Licensing Agreement With Calimmune For ddRNAi Technology 44
CSL Raises USD200 Million in Private Placement of 3.32% Debt Securities Due 2029 45
CSL Raises USD150 Million in Private Placement of 3.47% Debt Securities Due 2032 46
CSL Raises USD100 Million in Private Placement of 3.77% Debt Securities Due 2037 47
CSL Raises USD250 Million in Private Placement of 3.17% Debt Securities Due 2027 48
CSL Raises USD258 Million in Private Placement of 0.955% Debt Securities Due 2025 49
CSL Raises USD155 Million in Private Placement of 0.755% Debt Securities Due 2023 50
CSL Raises USD100 Million in Private Placement of 3.63% Debt Securities Due 2025 51
CSL Raises USD200.5 Million in Private Placement of 1.93% Debt Securities Due 2024 52
CSL Raises USD134 Million in Private Placement of 2.1% Debt Securities Due 2026 53
CSL Raises USD134 Million in Private Placement of 1.65% Debt Securities Due 2022 54
CSL Completes Private Placement Of Debt Securities Due 2023 For US$150 Million 55
CSL Completes Private Placement Of Debt Securities Due 2018 For US$100 Million 56
CSL Completes Private Placement Of Debt Securities Due 2020 For US$150 Million 57
CSL Completes Private Placement Of Debt Securities Due 2025 For US$100 Million 58
Paragon Care to Acquire Immunohaematology Business Unit from Seqirus for USD6.4 Million 59
CSL to Acquire Remaining 20% Stake in Wuhan Zhong Yuan Rui De Biological Products from Humanwell Healthcare Group for USD102 Million 60
CSL Behring Acquires Calimmune 61
CSL Acquires 80% Equity Stake in Wuhan Zhong Yuan Rui De Biological Products from Humanwell Healthcare Group for USD352 Million 62
CSL Ltd, Key Competitors 63
CSL Ltd, Key Employees 64
CSL Ltd, Other Locations 65
CSL Ltd, Subsidiaries 65

List of Figures
CSL Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
CSL Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
CSL Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
CSL Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
CSL Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
CSL Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
CSL Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
CSL Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
CSL Ltd, Medical Devices Deals, 2012 to YTD 2018 13

★海外企業調査レポート[CSL Ltd (CSL):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • XCyton Diagnostics Ltd-医療機器分野:企業M&A・提携分析
    Summary XCyton Diagnostics Ltd (Xcyton) is a molecular biology company that develops and markets diagnostics products and services. The company provides ELISA kit for the detection of HIV infection; ELISA products for the detection of Neurocysticercosis, Hepatitis C and Japanese encephalitis. It pro …
  • BioTime Inc (BTX):医療機器:M&Aディール及び事業提携情報
    Summary BioTime Inc (BioTime) is a clinical-stage biotechnology company. It focuses on developing cures or treatments based on its core proprietary technology platforms for cell replacement and cell/drug delivery.The company's aesthetics products under development include Renevia , a potential treat …
  • Primearth EV Energy Co Ltd:企業の戦略的SWOT分析
    Primearth EV Energy Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Parsons Corporation:企業の戦略・SWOT・財務分析
    Parsons Corporation - Strategy, SWOT and Corporate Finance Report Summary Parsons Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • SpareBank 1 Nord-Norge:企業の戦略・SWOT・財務分析
    SpareBank 1 Nord-Norge - Strategy, SWOT and Corporate Finance Report Summary SpareBank 1 Nord-Norge - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Bloomin’ Brands Inc:企業の戦略・SWOT・財務分析
    Bloomin' Brands Inc - Strategy, SWOT and Corporate Finance Report Summary Bloomin' Brands Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • OraSolv AB (OS):企業の財務・戦略的SWOT分析
    OraSolv AB (OS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • PT Elnusa Tbk (ELSA):企業の財務・戦略的SWOT分析
    Summary PT Elnusa Tbk (PT Elnusa), a subsidiary of PT Pertamina (Persero), is an oil and gas company that offers geo science services, and drilling and oilfield services. The company's geo science services include seismic data acquisition, seismic data measurement, seismic data processing, and non s …
  • Insys Therapeutics Inc (INSY)-製薬・医療分野:企業M&A・提携分析
    Summary Insys Therapeutics Inc (Insys) is a specialty pharmaceutical company, which discovers, develops and commercializes novel drug delivery systems. The company’s flagship product, Subsys is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients. Its lead prod …
  • Spine Injury Solutions Inc (SPIN):企業の財務・戦略的SWOT分析
    Summary Spine Injury Solutions Inc (SPIN), formerly Spine Pain Management Inc is a medical service provider that provides medical technology and healthcare management solutions for liability spine injuries. The company provides services such as clinical management, and billing and collection of medi …
  • Egdon Resources Plc (EDR):石油・ガス:M&Aディール及び事業提携情報
    Summary Egdon Resources Plc (Egdon) is oil and gas company that offers exploration and production services. The company explores and develops petroleum and natural gas assets in East Midlands, North East England, North West England, and Southern England, the UK. Its project site includes Wressle, No …
  • Astellas Pharma Inc.:企業の戦略・SWOT・財務情報
    Astellas Pharma Inc. - Strategy, SWOT and Corporate Finance Report Summary Astellas Pharma Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Valneva SE:企業のM&A・事業提携・投資動向
    Valneva SE - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Valneva SE Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • KLM Catering Services Schiphol bv:企業の戦略・SWOT・財務分析
    KLM Catering Services Schiphol bv - Strategy, SWOT and Corporate Finance Report Summary KLM Catering Services Schiphol bv - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Northwest Biotherapeutics Inc (NWBO):製薬・医療:M&Aディール及び事業提携情報
    Summary Northwest Biotherapeutics Inc (NW Bio) is a development stage biotechnology company. It discovers and develops immunotherapy products to treat cancer. The company by utilizing its proprietary technology platform, DCVax, developed a robust pipeline of therapeutic product candidates. DCVax is …
  • Krosaki Harima Corporation:企業の戦略・SWOT・財務情報
    Krosaki Harima Corporation - Strategy, SWOT and Corporate Finance Report Summary Krosaki Harima Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Bashneft (BANE):企業の財務・戦略的SWOT分析
    Bashneft (BANE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Lisega SE:企業の戦略的SWOT分析
    Lisega SE - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Optiscan Imaging Limited (OIL)-医療機器分野:企業M&A・提携分析
    Summary Optiscan Imaging Limited (Optiscan) is a technology and product development company. It focuses on the development and application of microscopic imaging technologies for medical procedures. The company’s key product is ViewnVivo, a miniaturized fluorescence endo-microscope platform that bri …
  • Takuma Co Ltd (6013):企業の財務・戦略的SWOT分析
    Takuma Co Ltd (6013) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆